

381 University, Nagasaki, Japan. We thank Konosuke Morimoto of the Institute of Tropical
382 Medicine, Nagasaki University, for his support and advice.

383 **References**

- 384 Matanock, A., Gierke, R., Kobayashi, M., Leidner, A. & Pilishvili, T. (2019). Use of 13-
385 Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal
386 Polysaccharide Vaccine Among Adults Aged ≥ 65 Years: Updated
387 Recommendations of the Advisory Committee on Immunization Practices. *Morbidity and*
388 *Mortality Weekly Report. Surveillance Summaries*, Vol. 68 / No. 46, 1069-1075.
- 389 Bonten, M. J., Huijts, S. M., Bolkenbaas, M., Webber, C., Patterson, S., Gault, S., van
390 Werkhoven, C. H., van Deursen, A. M., Sanders, E. A., Verheij, T. J., Patton, M.,
391 McDonough, A., Moradoghli-Haftvani, A., Smith, H., Mellelieu, T., Pride, M. W.,
392 Crowther, G., Schmoele-Thoma, B., Scott, D. A., Jansen, K. U., Lobatto, R.,
393 Oosterman, B., Visser, N., Caspers, E., Smorenburg, A., Emini, E. A., Gruber, W.
394 C., & Grobbee, D. E. (2015). Polysaccharide conjugate vaccine against
395 pneumococcal pneumonia in adults. *New England Journal of Medicine*, 372(12),
396 1114-1125. <https://doi.org/10.1056/NEJMoa1408544>
- 397 de Roux, A., Schmöle-Thoma, B., Siber, G. R., Hackell, J. G., Kuhnke, A., Ahlers, N.,
398 Baker, S. A., Razmpour, A., Emini, E. A., Fernsten, P. D., Gruber, W. C., Lockhart,

- 399 S., Burkhardt, O., Welte, T., & Lode, H. M. (2008). Comparison of pneumococcal
400 conjugate polysaccharide and free polysaccharide vaccines in elderly adults:
401 conjugate vaccine elicits improved antibacterial immune responses and
402 immunological memory. *Clinical Infectious Diseases*, *46*(7), 1015-1023.
403 <https://doi.org/10.1086/529142>
- 404 Diao, W. Q., Shen, N., Yu, P. X., Liu, B. B., & He, B. (2016). Efficacy of 23-valent
405 pneumococcal polysaccharide vaccine in preventing community-acquired
406 pneumonia among immunocompetent adults: A systematic review and meta-
407 analysis of randomized trials. *Vaccine*, *34*(13), 1496-1503.
408 <https://doi.org/10.1016/j.vaccine.2016.02.023>
- 409 National Institute of Infectious Diseases (2018). Fact sheet of the 23-valent pneumococcal
410 polysaccharide vaccine Retrieved January 5, 2021 from
411 [https://www.mhlw.go.jp/file/05-Shingikai-10601000-](https://www.mhlw.go.jp/file/05-Shingikai-10601000-Daijinkanboukouseikagakuka-Kouseikagakuka/0000184910_1.pdf)
412 [Daijinkanboukouseikagakuka-Kouseikagakuka/0000184910_1.pdf](https://www.mhlw.go.jp/file/05-Shingikai-10601000-Daijinkanboukouseikagakuka-Kouseikagakuka/0000184910_1.pdf)
- 413 Fukusumi, M., Chang, B., Tanabe, Y., Oshima, K., Maruyama, T., Watanabe, H.,
414 Kuronuma, K., Kasahara, K., Takeda, H., Nishi, J., Fujita, J., Kubota, T.,
415 Sunagawa, T., Matsui, T., & Oishi, K. (2017). Invasive pneumococcal disease
416 among adults in Japan, April 2013 to March 2015: disease characteristics and

- 417 serotype distribution. *BMC Infectious Diseases*, 17(1), 2.
418 <https://doi.org/10.1186/s12879-016-2113-y>
- 419 Greenberg, R. N., Gurtman, A., Frenck, R. W., Strout, C., Jansen, K. U., Trammel, J.,
420 Scott, D. A., Emini, E. A., Gruber, W. C., & Schmoele-Thoma, B. (2014).
421 Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-
422 valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve
423 adults 60-64 years of age. *Vaccine*, 32(20), 2364-2374.
424 <https://doi.org/10.1016/j.vaccine.2014.02.002>
- 425 Hoshi, S. L., Kondo, M., & Okubo, I. (2015). Economic Evaluation of Immunisation
426 Programme of 23-Valent Pneumococcal Polysaccharide Vaccine and the Inclusion
427 of 13-Valent Pneumococcal Conjugate Vaccine in the List for Single-Dose
428 Subsidy to the Elderly in Japan. *PloS One*, 10(10), e0139140.
429 <https://doi.org/10.1371/journal.pone.0139140>
- 430 Ikeda, S. (2017). The guideline for the cost-effectiveness analysis of vaccination.
431 Retrieved January 16, 2021 from https://www.mhlw.go.jp/file/05-Shingikai-10601000-Daijinkanboukouseikagakuka-Kouseikagakuka/0000184902_1.pdf
432
- 433 Ikeda, S. (2018). Policy Application of Health Technology Assessment: Economic
434 Evaluation of Vaccination. *Jpn J Pharmacoepidemiol.*, 23(1), 11-17.

- 435 Ikeda, S., Igarashi, A., & Shiroiwa, T. (2020). The evaluation of the cost-effectiveness
436 analysis of pneumococcal vaccines from the standpoint of society. Retrieved
437 January 16, 2021 from [https://www.life-silver.com/global-](https://www.life-silver.com/global-image/units/upfiles/41255-1-20200821114629_b5f3f3585585da.pdf)
438 [image/units/upfiles/41255-1-20200821114629_b5f3f3585585da.pdf](https://www.life-silver.com/global-image/units/upfiles/41255-1-20200821114629_b5f3f3585585da.pdf)
- 439 Jackson, L. A., Gurtman, A., van Cleeff, M., Frenck, R. W., Treanor, J., Jansen, K. U.,
440 Scott, D. A., Emini, E. A., Gruber, W. C., & Schmoele-Thoma, B. (2013).
441 Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine
442 or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal
443 responses following subsequent pneumococcal vaccination in adults 50 years and
444 older. *Vaccine*, 31(35), 3594-3602. <https://doi.org/10.1016/j.vaccine.2013.04.084>
- 445 Statistics Bureau of Japan. 2015 Population Census Retrieved December 28, 2020 from
446 <https://www.stat.go.jp/english/data/kokusei/index.html>
- 447 Jiang, Y., Yang, X., Taniguchi, K., Petigara, T., & Abe, M. (2018). A cost-effectiveness
448 analysis of revaccination and catch-up strategies with the 23-valent pneumococcal
449 polysaccharide vaccine (PPV23) in older adults in Japan. *Journal of Medical*
450 *Economics*, 21(7), 687-697. <https://doi.org/10.1080/13696998.2018.1465272>
- 451 Konomura, K., Nagai, H., & Akazawa, M. (2017). Economic burden of community-
452 acquired pneumonia among elderly patients: a Japanese perspective. *Pneumonia*,

- 453 9(1). <https://doi.org/10.1186/s41479-017-0042-1>
- 454 Kraicer-Melamed, H., O'Donnell, S., & Quach, C. (2016). The effectiveness of
455 pneumococcal polysaccharide vaccine 23 (PPV23) in the general population of 50
456 years of age and older: A systematic review and meta-analysis. *Vaccine*, *34*(13),
457 1540-1550. <https://doi.org/10.1016/j.vaccine.2016.02.024>
- 458 Ladhani, S. N., Collins, S., Djennad, A., Sheppard, C. L., Borrow, R., Fry, N. K., Andrews,
459 N. J., Miller, E., & Ramsay, M. E. (2018). Rapid increase in non-vaccine serotypes
460 causing invasive pneumococcal disease in England and Wales, 2000-17: a
461 prospective national observational cohort study. *Lancet Infectious Diseases*, *18*(4),
462 441-451. [https://doi.org/10.1016/s1473-3099\(18\)30052-5](https://doi.org/10.1016/s1473-3099(18)30052-5)
- 463 Materials from the 2nd Meeting of the Subcommittee on Vaccine Evaluation, Section on
464 Basic Policies for Immunization, Subcommittee on Immunization and Vaccines,
465 Health Sciences Council. (2015). Retrieved January 14, 2021 from
466 <https://www.mhlw.go.jp/stf/shingi2/0000107224.html>
- 467 Miller, E., Andrews, N. J., Waight, P. A., Slack, M. P., & George, R. C. (2011). Herd
468 immunity and serotype replacement 4 years after seven-valent pneumococcal
469 conjugate vaccination in England and Wales: an observational cohort study.
470 *Lancet Infectious Diseases*, *11*(10), 760-768. <https://doi.org/10.1016/s1473->

- 471 3099(11)70090-1
- 472 Moberley, S., Holden, J., Tatham, D. P., & Andrews, R. M. (2013). Vaccines for
473 preventing pneumococcal infection in adults. *Cochrane Database of Systematic
474 Reviews*(1), CD000422. <https://doi.org/10.1002/14651858.CD000422.pub3>
- 475 Morimoto, K., Suzuki, M., Ishifuji, T., Yaegashi, M., Asoh, N., Hamashige, N., Abe, M.,
476 Aoshima, M., Ariyoshi, K., & Adult Pneumonia Study, G.-J. (2015). The burden
477 and etiology of community-onset pneumonia in the aging Japanese population: a
478 multicenter prospective study. *PloS One*, *10*(3), e0122247.
479 <https://doi.org/10.1371/journal.pone.0122247>
- 480 Niki, Y., Kawakami, K., Maruyama, T., Ikematsu, H., Aoki, Y., & Watanabe, H. (2016).
481 Guidance for vaccination in adult, 2016 Revised Edition. *The Journal of the
482 Japanese Society of Internal Medicine*, *105*(8), 1472-1488.
- 483 Nishikawa, A. M., Sartori, A. M. C., Mainardi, G. M., Freitas, A. C., Itria, A., Novaes, H.
484 M. D., & de Soarez, P. C. (2018). Systematic review of economic evaluations of
485 the 23-valent pneumococcal polysaccharide vaccine (PPV23) in individuals 60
486 years of age or older. *Vaccine*, *36*(19), 2510-2522.
487 <https://doi.org/10.1016/j.vaccine.2018.03.070>
- 488 Patterson, S., Webber, C., Patton, M., Drews, W., Huijts, S. M., Bolkenbaas, M., Gruber,

- 489 W. C., Scott, D. A., & Bonten, M. J. M. (2016). A post hoc assessment of duration
490 of protection in CAPiTA (Community Acquired Pneumonia immunization Trial
491 in Adults). *Trials in Vaccinology*, 5, 92-96.
492 <https://doi.org/10.1016/j.trivac.2016.04.004>
- 493 Health and Labour Science Research Grants (Strategic Integrated Scientific Research
494 Project). (2019). Guideline for Preparing Cost-Effectiveness Evaluation to the
495 Central Social Insurance Medical Council ver.2. Retrieved December 28, 2020
496 from [guideline for cost-effectiveness evaluation in Japan \(niph.go.jp\)](http://www.niph.go.jp)
- 497 Sando, E., Suzuki, M., Furumoto, A., Asoh, N., Yaegashi, M., Aoshima, M., Ishida, M.,
498 Hamaguchi, S., Otsuka, Y., & Morimoto, K. (2019). Impact of the pediatric 13-
499 valent pneumococcal conjugate vaccine on serotype distribution and clinical
500 characteristics of pneumococcal pneumonia in adults: The Japan Pneumococcal
501 Vaccine Effectiveness Study (J-PAVE). *Vaccine*, 37(20), 2687-2693.
502 <https://doi.org/10.1016/j.vaccine.2019.04.009>
- 503 Shimbashi, R., Chang, B., Tanabe, Y., Takeda, H., Watanabe, H., Kubota, T., Kasahara,
504 K., Oshima, K., Nishi, J., Maruyama, T., Kuronuma, K., Fujita, J., Ikuse, T., Kinjo,
505 Y., Suzuki, M., Kerdsin, A., Shimada, T., Fukusumi, M., Tanaka-Taya, K., Matsui,
506 T., Sunagawa, T., Ohnishi, M., Oishi, K., & Adult, I. P. D. S. G. (2019).

- 507 Epidemiological and clinical features of invasive pneumococcal disease caused
508 by serotype 12F in adults, Japan. *PloS One*, 14(2), e0212418.
509 <https://doi.org/10.1371/journal.pone.0212418>
- 510 Shimbashi, R., Suzuki, M., Chang, B., Watanabe, H., Tanabe, Y., Kuronuma, K., Oshima,
511 K., Maruyama, T., Takeda, H., Kasahara, K., Fujita, J., Nishi, J., Kubota, T.,
512 Tanaka-Taya, K., Matsui, T., Sunagawa, T., Oishi, K., & Adult, I. P. D. S. G.
513 (2020). Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine against
514 Invasive Pneumococcal Disease in Adults, Japan, 2013-2017. *Emerging*
515 *Infectious Diseases*, 26(10), 2378-2386. <https://doi.org/10.3201/eid2610.191531>
- 516 Shiroiwa, T., Fukuda, T., Ikeda, S., Igarashi, A., Noto, S., Saito, S., & Shimozuma, K.
517 (2016). Japanese population norms for preference-based measures: EQ-5D-3L,
518 EQ-5D-5L, and SF-6D. *Quality of Life Research*, 25(3), 707-719.
519 <https://doi.org/10.1007/s11136-015-1108-2>
- 520 Shiroiwa, T., Sung, Y. K., Fukuda, T., Lang, H. C., Bae, S. C., & Tsutani, K. (2010).
521 International survey on willingness-to-pay (WTP) for one additional QALY
522 gained: what is the threshold of cost effectiveness? *Health Economics*, 19(4), 422-
523 437. <https://doi.org/10.1002/hec.1481>
- 524 Sunagawa, T., & Fukusumi, M. (2018). Invasive pneumococcal diseases from 2013 to

525 2017, Japan.

526 Suzuki, M., Dhoubhadel, B. G., Ishifuji, T., Yasunami, M., Yaegashi, M., Asoh, N., Ishida,
527 M., Hamaguchi, S., Aoshima, M., Ariyoshi, K., & Morimoto, K. (2017). Serotype-
528 specific effectiveness of 23-valent pneumococcal polysaccharide vaccine against
529 pneumococcal pneumonia in adults aged 65 years or older: a multicentre,
530 prospective, test-negative design study. *The Lancet Infectious Diseases*, *17*(3),
531 313-321. [https://doi.org/10.1016/s1473-3099\(17\)30049-x](https://doi.org/10.1016/s1473-3099(17)30049-x)

532 Ministry of Health, Labour and Welfare. (2019). The abridged life table in 2019.
533 Retrieved January 16, 2021
534 from <https://www.mhlw.go.jp/toukei/saikin/hw/life/life19/index.html>

535 Watanabe, A., Inoue, S., & Ohno, T. (2015). Cost-effectiveness analysis in regard to
536 elderly persons in Japan, of PCV13 and PPV23 sequential dosing against PPV23
537 single dose as the routine vaccination program *Respiratory Medicine*, *27*(5), 444-
538 454